GLT25D1 CRISPR/Cas9 KO Plasmid (h): sc-405631
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GLT25D1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the GLT25D1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GLT25D1 CRISPR/Cas9 KO Plasmid (h) | sc-405631 | 20 µg | $397.00 |
Overview
COLGALT1 encodes GLT25D1, an endoplasmic reticulum–localized collagen beta(1-O)galactosyltransferase that catalyzes galactosylation of hydroxylysine residues during collagen post-translational modification. This reaction is part of the sequential glycosylation pathway that supports proper collagen folding, stability, and secretion, influencing extracellular matrix assembly and basement membrane organization. GLT25D1 activity intersects with ER proteostasis and secretory trafficking, where altered collagen glycosylation can perturb matrix–cell signaling and tissue mechanics. Genetic disruption or dysregulation of collagen glycosylation enzymes, including COLGALT1, has been linked to connective tissue and developmental phenotypes and is studied in the context of matrix-driven fibrosis, musculoskeletal disorders, and tumor microenvironment remodeling.
GLT25D1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the COLGALT1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the COLGALT1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the COLGALT1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish GLT25D1 protein expression.
This CRISPR knockout system enables efficient generation of COLGALT1-deficient cell models for investigation of GLT25D1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting COLGALT1 exon(s) critical for GLT25D1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple COLGALT1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by GLT25D1 CRISPR/Cas9 KO Plasmid (h) and GLT25D1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the COLGALT1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by GLT25D1 HDR Plasmid (h) and GLT25D1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by COLGALT1 homology arms to support homology-directed repair at defined COLGALT1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.